ArticlePeerJ2025
Identification of immunological and prognostic value of SHROOM2 in pan-cancer and experimental verification of its role in promoting malignant phenotypes in breast cancer.
Article in PeerJ, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Identification of pyroptosis and hypoxia related molecular subtypes and a prognostic signature in colorectal cancer.Discover oncology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: This study aimed to investigate the relationship between Shroom Family Member 2 (SHROOM2) expression and immune features, survival outcomes, and tumor mutational burden (TMB) across various cancer types, as well as its impact on the aggressive behavior of breast cancer (BC). Methods: RNA sequencing and clinical survival data were retrieved from the TCGA-BRCA and TCGA-PANCANCER datasets within The Cancer Genome Atlas (TCGA) database. Survival analyses were performed to assess the association between SHROOM2 expression and clinical outcomes across different cancer types. Gene set enrichment analysis (GSEA) was applied to identify potential mechanisms associated with differentially expressed genes in BC. Spearman correlation and Wilcoxon tests were used to evaluate the relationships between SHROOM2 levels and immune characteristics, TMB, or drug sensitivity. Additionally, the effects of SHROOM2 on BC cells were assessed through reverse transcription-quantitative polymerase chain reaction (PCR), cell counting kit-8 (CCK-8) assay, transwell assay, and wound healing assay. Results: SHROOM2 was overexpressed in a range of cancers, and its upregulation was associated with poor clinical outcomes. It was significantly correlated with immunomodulators, immune checkpoints, and immune cell infiltration in pan-cancer. Moreover, it showed an association with TMB and drug sensitivity in BC. Increased SHROOM2 expression enhanced the proliferative, migratory, and invasive capabilities of BC cells Conclusion: High SHROOM2 expression is linked to poor prognosis in BC, supporting its potential as both an immunological and predictive biomarker.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.